Arizona State Retirement System raised its position in Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 1.9% during ...

In a regulatory filing, Cytokinetics (CYTK) disclosed that at upcoming investor conferences, the company will be providing, and is hereby ...

Morgan Stanley notes that Cytokinetics (CYTK) released an 8-K providing a brief update regarding the regulatory status of aficamten for the ...

In this article, we are going to take a look at where Cytokinetics, Incorporated (NASDAQ:CYTK) stands against the other oversold pharma stocks to buy according to analysts. On February 20 ...

Cytokinetics Inc. has recently seen multiple executives selling portions of their stock holdings, all reportedly to cover tax ...

Cytokinetics (CYTK) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook ...

Market forces rained on the parade of Cytokinetics, Incorporated (NASDAQ:CYTK) shareholders today, when the analysts downgraded their forecasts for this year. Revenue estimates were cut sharply as ...

Analysts at B. Riley cut their FY2025 earnings per share estimates for Cytokinetics in a note issued to investors on Wednesday, March 5th. B. Riley analyst M. Mamtani now anticipates that the ...

On Wednesday, 12 March 2025, Cytokinetics (NASDAQ: CYTK) presented at the Barclays 27th Annual Global Healthcare Conference. The company shared its strategic plans for launching aficamten ...

While the job market is tough for life sciences professionals right now, it won’t always be. Employers must continue striving ...

CYTK reports a wider-than-expected Q4 loss as operating expenses increase. CYTK is gearing up to launch lead candidate ...